Nautilus Biotechnology, Inc. — Form SCHEDULE 13D/A
Filed November 3, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 72/100
What the filing says
Perceptive Life Sciences Master Fund, Ltd. sold approximately 5,472,901 shares of Nautilus Biotechnology between July 28 and October 26, 2026, at prices ranging from $1.31 to $3.12 per share, for aggregate proceeds of ~$10.2M. This represents a substantial block disposition by what appears to be a major shareholder during a compressed timeframe.
Why this rating
Liquidation of ~5.5M shares (~$10.2M proceeds) is 28% of Nautilus's current market cap; signals loss of confidence or capital reallocation by major holder. Relative to $35.8M company, highly material; suggests shareholder stress or negative view.
Price action (we called it negative)
before filing · preread $2.34 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.